Update on Zoladex treatment access for people with breast cancer

Update on Zoladex treatment access for people with breast cancer

07 May 2026

BCNA says the decision may be distressing for people currently using the treatment and has raised concerns about how the change will affect patients.

The organisation is asking AstraZeneca to provide further detail on the evidence behind the decision, particularly for people who are currently prescribed the 3.6mg version.

An alternative, the Zoladex 10.8mg implant, will remain available. However, BCNA says work is underway to understand how this option would be accessed if it is not listed on the Pharmaceutical Benefits Scheme (PBS), including possible cost impacts for patients.

BCNA is also working with clinicians, stakeholders, and the company to clarify options and reduce disruption for people living with breast cancer.

At this stage, supplies of Zoladex 3.6mg will continue while discussions take place, and BCNA says it is working with health professionals and government to support a transition plan.

People affected are being encouraged to contact the BCNA Helpline for support and further information as updates become available.

https://www.bcna.org.au/

Source: Breast Cancer Network Australia (BCNA)

Categories

Popular Posts

Recent Posts

Tags